Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
Hlavní autor: | Flora, Sanzida Alam |
---|---|
Další autoři: | Azam, Faruque |
Médium: | Diplomová práce |
Jazyk: | English |
Vydáno: |
Brac University
2024
|
Témata: | |
On-line přístup: | http://hdl.handle.net/10361/23693 |
Podobné jednotky
-
A review on Bruton's Tyrosine Kinase inhibitors to outline the scopes of further advancements in the treatment of cancer
Autor: Khan, Muidul Hasan
Vydáno: (2024) -
Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer
Autor: Paul, Pulock
Vydáno: (2024) -
Impact of treatment size and therapy type in phase II clinical trials of non-small cell lung cancer
Autor: Rahman, Tasnim
Vydáno: (2024) -
A review on cyclin-dependent kinase 7 (CDK7) Inhibitors as anticancer agents
Autor: Sorno, Rubina Haque
Vydáno: (2024) -
Efficacy analysis and prediction in phase II clinical trials of non-small cell Lung Cancer
Autor: Hoque, Ismoth Ara
Vydáno: (2024)